These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 28947723)
1. [EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism]. Kaymaz C Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):1-7. PubMed ID: 28947723 [TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. Imberti D; Pomero F; Mastroiacovo D Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579 [TBL] [Abstract][Full Text] [Related]
4. Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. Weitz JI; Chan NC Thromb Haemost; 2019 May; 119(5):689-694. PubMed ID: 30808045 [TBL] [Abstract][Full Text] [Related]
5. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Weitz JI; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Holberg G; Kakkar A; Lensing AW; Prins M; Haskell L; van Bellen B; Verhamme P; Wells PS; Prandoni P; Thromb Haemost; 2015 Aug; 114(3):645-50. PubMed ID: 25994838 [TBL] [Abstract][Full Text] [Related]
6. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Prandoni P; Lensing AWA; Prins MH; Gebel M; Pap AF; Homering M; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Cohen AT; Davidson BL; van Bellen B; Verhamme P; Wells PS; Yuan Z; Levitan B; Weitz JI Thromb Res; 2018 Aug; 168():121-129. PubMed ID: 30064683 [TBL] [Abstract][Full Text] [Related]
7. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D; Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317 [TBL] [Abstract][Full Text] [Related]
8. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. Khorana AA; Weitz JI Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417 [TBL] [Abstract][Full Text] [Related]
9. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Prins MH; Lensing AWA; Prandoni P; Wells PS; Verhamme P; Beyer-Westendorf J; Bauersachs R; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Kakkar AK; van Bellen B; Pap AF; Homering M; Tamm M; Weitz JI Blood Adv; 2018 Apr; 2(7):788-796. PubMed ID: 29632234 [TBL] [Abstract][Full Text] [Related]
10. Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. Wells PS; Lensing AWA; Haskell L; Levitan B; Laliberté F; Durkin M; Ashton V; Xiao Y; Crivera C; Lejeune D; Schein J; Lefebvre P J Med Econ; 2018 Jun; 21(6):587-594. PubMed ID: 29469638 [TBL] [Abstract][Full Text] [Related]
20. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]